Guillain-Barre Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Guillain-Barre Syndrome Pipeline Drugs Market Overview

Guillain-Barre syndrome (GBS) is a disorder in which the body’s immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost paralyzed.

The Guillain-Barre Syndrome pipeline drugs market research report provides comprehensive information on the Guillain-Barre Syndrome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in GBS-targeted therapeutics development with respective active and dormant or discontinued projects.

GBS Pipeline Drugs Market - Competitive Landscape

The leading companies in the GBS pipeline drugs market are Cresence AS, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Annexon Inc, Cellenkos Inc, Chugai Pharmaceutical Co Ltd, and others. Cresence AS had the highest number of GBS drugs in development in 2022. Cresence AS (Cresence) develops new drugs for neurodegenerative disorders. Cresence is headquartered in Oslo, Norway.

GBS Pipeline Drugs Market Analysis, by Companies, 2022(%)

Buy the Full Report to Know More about the Leading Guillain-Barre Syndrome Drugs Pipeline Drugs Market Players, Download a Free Report Sample

GBS Pipeline Drugs Market Segmentation by Target

The key targets of the GBS pipeline drugs market are Complement C5, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Complement C1q Subcomponent, and others. Complement C5 was the top target in the GBS pipeline drugs market in 2022.

GBS Pipeline Drugs Market Analysis, by Target, 2022(%)

Buy the Full Report for More GBS Pipeline Drugs Market Target Insights, Download a Free Report Sample

GBS Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action of the GBS pipeline drugs market are Complement C5 Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Complement C1q Subcomponent Inhibitor, and others. Complement C5 Inhibitor was the top MoA in the GBS pipeline drugs market in 2022.

GBS Pipeline Drugs Market Analysis, by Mechanisms of Action, 2022(%)

Buy the Full Report for More GBS Pipeline Drugs Market Mechanisms of Action Insights, Download a Free Report Sample

GBS Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the GBS pipeline drugs market are intravenous, oral, subcutaneous, inhalational, intravitreal, and ophthalmic. The intravenous RoA led the GBS pipeline drugs market in 2022.

GBS Pipeline Drugs Market Analysis, by Routes of Administration, 2022(%)

Buy the Full Report for More GBS Pipeline Drugs Market Routes of Administration Insights, Download a Free Report Sample

GBS Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the GBS pipeline drugs market are monoclonal antibody, small molecule, peptide, cell therapy, polymer, protein, recombinant enzyme, recombinant protein, and subunit vaccine. Monoclonal Antibody was the leading molecule type in the GBS pipeline drugs market in 2022.

GBS Pipeline Drugs Market Analysis, by Molecule Types, 2022(%)

To Know More About the Molecule Types in the GBS Pipeline Drugs Market, Download a Free Report Sample

Segments Covered in the Report

GBS Pipeline Drugs Target Outlook, 2022

• Complement C5
• Cannabinoid Receptor 1
• Cannabinoid Receptor 2
• Complement C1q Subcomponent
• Others

GBS Pipeline Drugs MoA Outlook, 2022

• Complement C5 Inhibitor
• Cannabinoid Receptor 1 Agonist
• Cannabinoid Receptor 2 Agonist
• Complement C1q Subcomponent Inhibitor
• Others

GBS Pipeline Drugs RoA Outlook, 2022

• Intravenous
• Oral
• Subcutaneous
• Inhalational
• Others

GBS Pipeline Drugs Molecule Type Outlook, 2022

• Monoclonal Antibody
• Small Molecule
• Peptide
• Cell Therapy
• Others

Scope

• The report provides a snapshot of the global therapeutic landscape for Guillain-Barre Syndrome (GBS)
• The report reviews Guillain-Barre Syndrome (GBS) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Guillain-Barre Syndrome (GBS) targeted therapeutics and enlists all their major and minor projects
• The report assesses Guillain-Barre Syndrome (GBS) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews the latest news and deals related to Guillain-Barre Syndrome (GBS) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain competitive advantage.
• Identify and understand the targeted therapy areas and indications for Guillain-Barre Syndrome (GBS). Identify the use of drugs for target identification and drug repurposing.
• Identify potential new clients or partners in the target demographic.
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
• Devise corrective measures for pipeline projects by understanding the Guillain-Barre Syndrome (GBS) development landscape.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.